Cullinan Oncology(CGEM) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results Investigational New Drug (IND) application for CLN-978 in systemic lupus erythematosus (SLE) remains on track to be filed in third quarter of 2024 Company to pursue rheumatoid arthritis (RA) as second autoimmune indication for CLN-978 development CLN-619 combination therapy data presented at ASCO demonstrated objective responses in oncogenic driver mutation NSCLC, which is typically unresponsive to ...